Summary of Key Information:
Reporting Period (Quarter/Year): Quarter and Half Year ended 30th September 2026 (Q2 FY27)
Nature of Filing / Announcement: Outcome of Board Meeting - Unaudited Financial Results
Audit Opinion:
Unmodified audit conclusion (clean opinion) expressed by statutory auditors N. A. Shah Associates LLP for both consolidated and standalone financial results.
Key Financial Highlights [₹ Crores]:
Consolidated Results:
Quarter ended 30.09.2026:
- Revenue from Operations: ₹640.22 (vs ₹578.96 in Q2 FY26 - 10.6% increase YoY)
- Total Income: ₹655.59
- Net Profit: ₹22.22 (vs ₹(11.89) in Q2 FY26)
- EPS: ₹3.16 Basic, ₹3.14 Diluted
Half Year ended 30.09.2026:
- Revenue from Operations: ₹1,272.84 (vs ₹1,105.56 in H1 FY26 - 15.1% increase YoY)
- Total Income: ₹1,303.82
- Net Profit: ₹63.69 (vs ₹(22.36) in H1 FY26)
- EPS: ₹9.05 Basic, ₹9.03 Diluted
Financial Position as at 30.09.2026:
- Cash and Cash Equivalents: ₹157.01 (decreased from ₹289.48 as at 31.03.2026)
- Total Debt: ₹474.56 (Borrowings: ₹32.35 non-current + ₹442.21 current)
- Other Equity: ₹2,767.35
Standalone Results:
Quarter ended 30.09.2026:
- Revenue from Operations: ₹401.90 (vs ₹356.90 in Q2 FY26 - 12.6% increase YoY)
- Total Income: ₹418.75
- Net Profit: ₹1.49 (vs ₹(39.93) in Q2 FY26)
- EPS: ₹0.21 Basic, ₹0.21 Diluted
Half Year ended 30.09.2026:
- Revenue from Operations: ₹768.17 (vs ₹741.15 in H1 FY26 - 3.6% increase YoY)
- Total Income: ₹801.74
- Net Profit: ₹7.02 (vs ₹(41.78) in H1 FY26)
- EPS: ₹1.00 Basic, ₹1.00 Diluted
Financial Position as at 30.09.2026:
- Cash and Cash Equivalents: ₹101.46 (decreased from ₹252.67 as at 31.03.2026)
- Total Debt: ₹46.72 (Borrowings: ₹32.35 non-current + ₹14.37 current)
- Other Equity: ₹2,622.93
Segment-wise Performance:
The Company has a single reportable segment i.e. 'Pharmaceuticals'.
Corporate Actions:
No dividend declarations, share splits, bonus issues, buybacks, or capital raising activities announced.
Exceptional Items:
Consolidated Q2 FY27: ₹24.26 crore expense - Provision for Claims related to UK legal proceedings against subsidiary Niche Generics Limited
Consolidated Q2 FY25: ₹58.26 crore expense - Interest on European Commission fine
Standalone FY26: ₹(226.98) crore income - Net gain on disposal of land & building (erstwhile Registered office) and reversal of provision for European commission fine
Significant Legal Matters:
1. European Commission Fine: Company and subsidiary Niche Generics Limited received demand order dated 17th September 2025 for payment of fine and interest aggregating to Euro 19.55 million, fully settled on 28th October 2025.
2. UK Legal Claim: Laboratories Servier filed claim against Company and Niche Generics Limited seeking contribution towards damages claimed by UK Health Authorities in relation to Perindopril proceedings. Provision of £1.9 million (₹24.26 crores) recognized for potential settlement.
Cash Flow Analysis:
Consolidated H1 FY27:
- Operating Activities: ₹(68.07) crore (negative due to working capital changes)
- Investing Activities: ₹(51.67) crore
- Financing Activities: ₹(11.20) crore
- Net decrease in Cash: ₹(130.94) crore
Standalone H1 FY27:
- Operating Activities: ₹(93.41) crore
- Investing Activities: ₹(46.14) crore
- Financing Activities: ₹(10.13) crore
- Net decrease in Cash: ₹(149.68) crore
Subsidiary Information:
Consolidation includes:
1. Niche Generics Limited, United Kingdom
2. Unichem Pharmaceuticals (USA), Inc., USA
3. Unichem SA (Pty) Limited, South Africa
4. Unichem Farmaceutica Do Brasil Ltda, Brazil
5. Unichem (China) Pvt. Ltd.
During H1 FY27, the Company invested USD 80,000 (₹0.76 crores) in redeemable preference shares in Unichem (China) Pvt Ltd.
Other Equity Items:
Remeasurement of net defined benefit plan resulted in ₹3.37 crore gain in Q2 FY27 consolidated.